Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoichi Aoki

Showing results (191-200 of 205) with videos related to

Pageof 21
Sort By:
Journal of Gynecologic Oncology|March 30, 2026
Effect of first-line poly(ADP-ribose) polymerase inhibitor on second-line platinum-based chemotherapy in epithelial ovarian cancerYusuke Toyohara, Mayu Yunokawa, Ryo Nimura, et al.
Cancer Science|July 6, 2022
Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE-826Shin Nishio, Kan Yonemori, Tomoka Usami, et al.
International Journal of Clinical Oncology|December 6, 2024
The efficacy and safety of lenvatinib plus pembrolizumab in vulnerable patients with metastatic or recurrent endometrial cancer: a single institution experienceMayu Yunokawa, Akiko Abe, Xiaofei Wang, et al.
European Journal of Cancer (Oxford, England : 1990)|January 7, 2015
Administration of standard-dose BEP regimen (bleomycin+etoposide+cisplatin) is essential for treatment of ovarian yolk sac tumourToyomi Satoh, Yoichi Aoki, Takahiro Kasamatsu, et al.
International Journal of Clinical Oncology|April 9, 2026
Prevalence and clinicopathologic features of mismatch repair-deficient endometrial cancer in Japanese patients younger than 50 years: a single-center prospective observational studyHidetaka Nomura, Akiko Abe, Atsushi Fusegi, et al.
Scientific Reports|January 8, 2022
Prognosis and adjuvant chemotherapy for patients with positive peritoneal cytology in stage IA endometrial cancerMotoko Kanno, Mayu Yunokawa, Makoto Nakabayashi, et al.
Oncogenesis|January 24, 2018
Novel therapeutic strategy for cervical cancer harboring FGFR3-TACC3 fusionsRyo Tamura, Kosuke Yoshihara, Tetsuya Saito, et al.
Scientific Reports|January 19, 2023
Impact of the coverage of risk-reducing salpingo-oophorectomy by the national insurance system for women with BRCA pathogenic variants in JapanHidetaka Nomura, Akiko Abe, Atsushi Fusegi, et al.
British Journal of Cancer|August 4, 2018
Phase III study of cisplatin with or without S-1 in patients with stage IVB, recurrent, or persistent cervical cancerYoichi Aoki, Kazunori Ochiai, Soyi Lim, et al.
Human Pathology|March 27, 2022
Discrepancies in pathological diagnosis of endometrial stromal sarcoma: a multi-institutional retrospective study from the Japanese clinical oncology groupHiroshi Yoshida, Akira Kikuchi, Hitoshi Tsuda, et al.
Pageof 21

Showing results (191-200 of 205) with videos related to

Sort By:
Pageof 21
Journal of Gynecologic Oncology|March 30, 2026
Effect of first-line poly(ADP-ribose) polymerase inhibitor on second-line platinum-based chemotherapy in epithelial ovarian cancerYusuke Toyohara, Mayu Yunokawa, Ryo Nimura, et al.
Cancer Science|July 6, 2022
Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE-826Shin Nishio, Kan Yonemori, Tomoka Usami, et al.
International Journal of Clinical Oncology|December 6, 2024
The efficacy and safety of lenvatinib plus pembrolizumab in vulnerable patients with metastatic or recurrent endometrial cancer: a single institution experienceMayu Yunokawa, Akiko Abe, Xiaofei Wang, et al.
European Journal of Cancer (Oxford, England : 1990)|January 7, 2015
Administration of standard-dose BEP regimen (bleomycin+etoposide+cisplatin) is essential for treatment of ovarian yolk sac tumourToyomi Satoh, Yoichi Aoki, Takahiro Kasamatsu, et al.
International Journal of Clinical Oncology|April 9, 2026
Prevalence and clinicopathologic features of mismatch repair-deficient endometrial cancer in Japanese patients younger than 50 years: a single-center prospective observational studyHidetaka Nomura, Akiko Abe, Atsushi Fusegi, et al.
Scientific Reports|January 8, 2022
Prognosis and adjuvant chemotherapy for patients with positive peritoneal cytology in stage IA endometrial cancerMotoko Kanno, Mayu Yunokawa, Makoto Nakabayashi, et al.
Oncogenesis|January 24, 2018
Novel therapeutic strategy for cervical cancer harboring FGFR3-TACC3 fusionsRyo Tamura, Kosuke Yoshihara, Tetsuya Saito, et al.
Scientific Reports|January 19, 2023
Impact of the coverage of risk-reducing salpingo-oophorectomy by the national insurance system for women with BRCA pathogenic variants in JapanHidetaka Nomura, Akiko Abe, Atsushi Fusegi, et al.
British Journal of Cancer|August 4, 2018
Phase III study of cisplatin with or without S-1 in patients with stage IVB, recurrent, or persistent cervical cancerYoichi Aoki, Kazunori Ochiai, Soyi Lim, et al.
Human Pathology|March 27, 2022
Discrepancies in pathological diagnosis of endometrial stromal sarcoma: a multi-institutional retrospective study from the Japanese clinical oncology groupHiroshi Yoshida, Akira Kikuchi, Hitoshi Tsuda, et al.
Pageof 21